|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
Validation & testing of novel therapeutic targets to treat osteosarcoma
If you have a question about this talk, please contact eric.rahrmann.
The Cambridge Institute Scientists’ Society (CISS) would like to invite you all to our biannual seminar series on 10 October 2016 at 13:30 in the CRUK CI Lecture Theatre
Our guest lecturer is: Assistant Prof. Branden Moriarity in the Department of Paediatrics, Division of Hematology/Oncology at the University of Minnesota. Branden is an expert in genome engineering with emphasis on animal models of rare paediatric cancers and immunotherapy. It will be a fantastic talk and we hope to see you all there!!
Talk title: Validation & testing of novel therapeutic targets to treat osteosarcoma
Research summary/interests: Pediatric cancer genetics, gene and immunotherapy, genome engineering. Dr. Moriarity’s laboratory is working on studying the genetics of pediatric cancer, including sarcomas and brain tumors, to identify novel therapeutic targets to better treat pediatric cancer patients. The Moriarity lab uses animal models and comparative genomics approaches to identify new candidate cancer genes. Once identified, candidate genes are functionally studied in human cancer and immortalized cell lines using cutting edge technologies, such as targeted nucleases. The primary targeted nucleases used in the Moriarity lab are the CRISPR /Cas9 and Transcriptional Activator-Like Effector (TALEN) systems, which are used to knockout genes, induce targeted sequence changes, activate and/or repress endogenous gene expression.
All welcome to attend.
Kind regards, CISS committee
This talk is part of the Cambridge Institute Scientists' Society series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsLinguistics PhD seminars Future of Sentience Cambridge Cambridge Immunology
Other talks'How cells interpret signalling by TGF-β superfamily ligands' Presentation: Challenge 3. Estimating Flood Probability Using Historical Data Cambridge-Lausanne Workshop 2018 - Day 2 Can we make people value IT security? Commodotech' Profits Verses Human & Environmental Health' - Enough Biology - Time for Political Action on Global 'Obesity' Crisis Solutions Cambridge - Corporate Finance Theory Symposium September 2017 - Day 2